197 related articles for article (PubMed ID: 34045078)
1. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors.
Tomaipitinca L; Russo E; Bernardini G
Mol Aspects Med; 2021 Aug; 80():100968. PubMed ID: 34045078
[TBL] [Abstract][Full Text] [Related]
2. Chemokine networks modulating natural killer cell trafficking to solid tumors.
Yao X; Matosevic S
Cytokine Growth Factor Rev; 2021 Jun; 59():36-45. PubMed ID: 33495094
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell homing and trafficking in tissues and tumors: from biology to application.
Ran GH; Lin YQ; Tian L; Zhang T; Yan DM; Yu JH; Deng YC
Signal Transduct Target Ther; 2022 Jun; 7(1):205. PubMed ID: 35768424
[TBL] [Abstract][Full Text] [Related]
4. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
[TBL] [Abstract][Full Text] [Related]
6. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
7. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
9. Mapping the chemotactic landscape in NK cells reveals subset-specific synergistic migratory responses to dual chemokine receptor ligation.
Lachota M; Zielniok K; Palacios D; Kanaya M; Penna L; Hoel HJ; Wiiger MT; Kveberg L; Hautz W; Zagożdżon R; Malmberg KJ
EBioMedicine; 2023 Oct; 96():104811. PubMed ID: 37741009
[TBL] [Abstract][Full Text] [Related]
10. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
11. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
12. Application of natural killer immunotherapy in blood cancers and solid tumors.
Sayegh M; Ma S; Yu J
Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
[TBL] [Abstract][Full Text] [Related]
13. Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.
Feigl FF; Stahringer A; Peindl M; Dandekar G; Koehl U; Fricke S; Schmiedel D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834542
[TBL] [Abstract][Full Text] [Related]
14. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
15. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
16. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
17. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.
Farnault L; Sanchez C; Baier C; Le Treut T; Costello RT
Clin Dev Immunol; 2012; 2012():421702. PubMed ID: 22899948
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
Tanaka J
Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
Huang R; Wen Q; Zhang X
J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
